PARAMETER |
St. JOHNS WORT |
TRICYCLIC ANTIDEPRESSANT (TCA) |
SEROTONIN REUPTAKE INHIBITORS (SSRI) |
Efficacy |
Almost the same as conventional antidepressants |
Effective treatment for depression |
First-line treatment for depression |
Safety |
Same as conventional antidepressants |
Safe use |
Safe use |
Most common adverse effect |
Less than conventional antidepressants |
Cardiac arrhythmia |
Serotoninergic syndrome |
Mechanism of action |
Inhibition of the reuptake of serotonin monoamine oxidase activity reduces GABA binding. |
Inhibition of the reuptake of serotonin and norepinephrine |
Inhibition of the reuptake of serotonin |
Cost |
Low |
Higher |
High |
Rate of discontinuation due to side effects |
Low |
Higher than St John's Wort |
Higher than St John's Wort |
Withdrawal symptoms rate |
Low |
Higher than St John's Wort |
Higher than St John's Wort |
Long-term antidepressant effects |
Limited data |
Well known long effectiveness |
Well known long effectiveness |
Approved by FDA |
No |
Yes |
Yes |
Drug interactions |
HIV drugs, ciclosporin, tacrolimus, digoxin, oxycodone, warfarin, etc. |
SSRI, anticholinergic, antihypertensive. antihistamine, etc. |
NSAIDs, aspirin, warfarin, and all drugs increase serotonin, etc. |